We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 30, 2020

Natalizumab vs Fingolimod in Active Relapsing MS

Multiple Sclerosis (Houndmills, Basingstoke, England)

 

Additional Info

Disclosure statements are available on the authors' profiles:

Multiple Sclerosis (Houndmills, Basingstoke, England)
BEST-MS: A Prospective Head-to-Head Comparative Study of Natalizumab and Fingolimod in Active Relapsing MS
Mult. Scler. 2020 Oct 30;[EPub Ahead of Print], M Cohen, L Mondot, F Bucciarelli, B Pignolet, DA Laplaud, S Wiertlewski, B Brochet, A Ruet, G Defer, N Derache, P Vermersch, H Zephir, M Debouverie, G Mathey, E Berger, C Cappé, P Labauge, C Carra, J De Seze, K Bigaut, D Brassat, C Lebrun-Frenay

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading